Related Experiment Video

Updated: Mar 17, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

Net prolongation of life in advanced heart failure: An intentional strategy of durable LVAD therapy followed by heart

Alexander M Bernhardt1, Manreet K Kanwar2, Michelle Kittleson3

  • 1Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|March 15, 2026
PubMed

Insights

Left ventricular assist device (LVAD) support and heart transplantation (HT) offer advanced heart failure treatment. For younger patients, LVAD as a first-line therapy may optimize long-term outcomes and extend treatment options.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Medical Technology

Background:

  • Heart failure (HF) and cardiogenic shock necessitate advanced surgical interventions like heart transplantation (HT) and left ventricular assist device (LVAD) support.
  • HT is the gold standard but limited for younger patients due to re-transplantation challenges.
  • LVAD technology has advanced, offering improved survival rates for younger individuals.

Purpose of the Study:

  • To evaluate the synergistic potential of LVAD and HT in advanced heart failure management.
  • To explore LVAD as a primary strategy for younger, transplant-eligible patients.
  • To optimize lifetime management for advanced heart failure patients.

Main Methods:

  • Comparative analysis of survival data for HT and LVAD.
  • Review of current trends in HF prevalence, organ availability, and allocation policies.
  • Assessment of LVAD as a first-line therapy in younger populations.

Main Results:

  • Median survival for HT is 10-13 years; for LVAD in younger patients, it exceeds 7 years.
  • LVAD offers a viable long-term solution for younger patients ineligible for re-transplantation.
  • Synergistic use of LVAD and HT is proposed for selected advanced HF patients.

Conclusions:

  • LVAD and HT should be viewed as complementary, not competing, therapies.
  • Intentional LVAD implantation as a first-line approach in younger adults may enhance long-term management.
  • This strategy could broaden therapeutic horizons for advanced heart failure.

Keywords:
heart failureheart transplantationleft ventricular assist deviceoutcomequality of life

More Related Videos

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.4K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
506
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
532
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
470